Evidence map›Paper›PMID 37536737›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH-Wild-Type Glioblastoma.

Nathalie L Albert, Debie V Nelwan, Daniel F Fleischmann, Stefanie Quach, Katharina von Rohr, Lena Kaiser, Nico Teske, Lena M Unterrainer, Laura M Bartos, Viktoria C Ruf and 13 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 1 country.

Nathalie L AlbertDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Debie V NelwanDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Daniel F FleischmannDepartment of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany.
Stefanie QuachDepartment of Neurosurgery, LMU University Hospital, LMU Munich, Munich, Germany.
Katharina von RohrDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Lena KaiserDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Nico TeskeGerman Cancer Consortium, Partner Site Munich, German Cancer Research Center, Munich, Germany.
Lena M UnterrainerDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Laura M BartosDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Viktoria C RufInstitute of Neuropathology, Faculty of Medicine, LMU Munich, Munich, Germany.
Matthias BrendelDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Markus J RiemenschneiderDepartment of Neuropathology, Regensburg University Hospital, Regensburg, Germany.
Christian WetzelDepartment of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany; and.
Jochen HermsInstitute of Neuropathology, Faculty of Medicine, LMU Munich, Munich, Germany.
Rainer RupprechtDepartment of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany; and.
Niklas ThonGerman Cancer Consortium, Partner Site Munich, German Cancer Research Center, Munich, Germany.
Joerg-Christian TonnGerman Cancer Consortium, Partner Site Munich, German Cancer Research Center, Munich, Germany.
Claus BelkaGerman Cancer Consortium, Partner Site Munich, German Cancer Research Center, Munich, Germany.
Peter BartensteinDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Louisa von BaumgartenGerman Cancer Consortium, Partner Site Munich, German Cancer Research Center, Munich, Germany.
Maximilian NiyaziGerman Cancer Consortium, Partner Site Munich, German Cancer Research Center, Munich, Germany.
Marcus UnterrainerGerman Cancer Consortium, Partner Site Munich, German Cancer Research Center, Munich, Germany.
Adrien HolzgreveDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany; adrien.holzgreve@med.uni-muenchen.de.
Ludwig-Maximilians-Universität München · DELMU Klinikum · DEGerman Cancer Research Center · DEUniversity of Regensburg · DEComprehensive Cancer Center Erlangen · DEGerman Center for Neurodegenerative Diseases · DEUniversity Hospital Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 18-kDa translocator protein (TSPO) is gaining recognition as a relevant target in glioblastoma imaging. However, data on the potential prognostic value of TSPO PET imaging in glioblastoma are lacking. Therefore, we investigated the association of TSPO PET imaging results with survival outcome in a homogeneous cohort of glioblastoma patients.

Indexed as

Brain NeoplasmsGlioblastomaHumansIsocitrate DehydrogenaseMiddle AgedPositron-Emission TomographyPrognosisReceptors, GABATemozolomideIsocitrate DehydrogenaseReceptors, GABATemozolomideTSPO protein, humangliomaprognosticationsurvival

Identifiers

PMID37536737
PMCPMC10586482
OpenAlexW4385554966

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.